Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Controlled, Parallel Group, 12-Week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 microg Once Daily With Open Label Tiotropium 18 microg Once Daily Versus Open Label Tiotropium 18 microg Once Daily in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease.

Next Previous
Trial Profile

A Randomized, Double-Blind, Controlled, Parallel Group, 12-Week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 microg Once Daily With Open Label Tiotropium 18 microg Once Daily Versus Open Label Tiotropium 18 microg Once Daily in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indacaterol (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms INTRUST-2
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 18 Aug 2011 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
  • 18 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 15 May 2011 Results presented at the 107th International Conference of the American Thoracic Society, according to a Novartis media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top